Raymond James & Associates Tekla Life Sciences Investors Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Tekla Life Sciences Investors stock. As of the latest transaction made, Raymond James & Associates holds 44,147 shares of HQL stock, worth $594,660. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,147
Previous 39,335 12.23%
Holding current value
$594,660
Previous $557,000 19.39%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
BUY
$14.26 - $15.78 $68,619 - $75,933
4,812 Added 12.23%
44,147 $665,000
Q2 2024

Jul 19, 2024
BUY
$12.79 - $14.27 $122,528 - $136,706
9,580 Added 32.2%
39,335 $557,000
Q1 2024

Apr 22, 2024
BUY
$13.38 - $14.33 $45,933 - $49,194
3,433 Added 13.04%
29,755 $405,000
Q4 2023

Jan 16, 2024
SELL
$11.35 - $13.6 $16,446 - $19,706
-1,449 Reduced 5.22%
26,322 $354,000
Q3 2023

Oct 24, 2023
SELL
$12.38 - $13.69 $1.69 Million - $1.87 Million
-136,694 Reduced 83.11%
27,771 $346,000
Q2 2023

Jul 25, 2023
SELL
$13.13 - $14.17 $1.91 Million - $2.07 Million
-145,739 Reduced 46.98%
164,465 $2.23 Million
Q1 2023

Apr 14, 2023
BUY
$13.37 - $14.94 $731,619 - $817,531
54,721 Added 21.42%
310,204 $4.32 Million
Q4 2022

Feb 08, 2023
BUY
$13.55 - $15.23 $1.16 Million - $1.31 Million
85,818 Added 50.58%
255,483 $3.63 Million
Q3 2022

Oct 25, 2022
BUY
$13.39 - $16.31 $2.11 Million - $2.57 Million
157,719 Added 1320.27%
169,665 $2.32 Million
Q2 2022

Aug 12, 2022
SELL
$13.11 - $17.02 $160,741 - $208,682
-12,261 Reduced 50.65%
11,946 $170,000
Q1 2022

May 11, 2022
SELL
$15.35 - $19.29 $877,544 - $1.1 Million
-57,169 Reduced 70.25%
24,207 $400,000
Q4 2021

Feb 08, 2022
BUY
$18.5 - $21.59 $319,902 - $373,334
17,292 Added 26.98%
81,376 $1.57 Million
Q3 2021

Nov 02, 2021
SELL
$20.27 - $22.67 $587 - $657
-29 Reduced 0.05%
64,084 $1.33 Million
Q2 2021

Aug 11, 2021
BUY
$19.14 - $21.44 $50,204 - $56,237
2,623 Added 4.27%
64,113 $1.38 Million
Q1 2021

May 14, 2021
BUY
$19.31 - $22.07 $587,255 - $671,192
30,412 Added 97.86%
61,490 $1.21 Million
Q4 2020

Feb 12, 2021
SELL
$16.8 - $20.21 $355,992 - $428,249
-21,190 Reduced 40.54%
31,078 $614,000
Q3 2020

Nov 04, 2020
SELL
$16.71 - $19.06 $25,967 - $29,619
-1,554 Reduced 2.89%
52,268 $919,000
Q2 2020

Jul 28, 2020
SELL
$14.22 - $18.38 $184,860 - $238,940
-13,000 Reduced 19.45%
53,822 $967,000
Q1 2020

Apr 21, 2020
SELL
$12.22 - $17.99 $259,980 - $382,737
-21,275 Reduced 24.15%
66,822 $1 Million
Q4 2019

Feb 12, 2020
SELL
$14.63 - $17.84 $1.15 Million - $1.41 Million
-78,806 Reduced 47.22%
88,097 $1.54 Million
Q3 2019

Nov 07, 2019
SELL
$15.09 - $17.09 $749,580 - $848,928
-49,674 Reduced 22.94%
166,903 $2.52 Million
Q2 2019

Aug 06, 2019
SELL
$15.54 - $17.47 $956,098 - $1.07 Million
-61,525 Reduced 22.12%
216,577 $3.65 Million
Q1 2019

May 06, 2019
SELL
$15.5 - $17.9 $282,177 - $325,869
-18,205 Reduced 6.14%
278,102 $4.76 Million
Q4 2018

Feb 11, 2019
SELL
$13.99 - $20.35 $219,195 - $318,843
-15,668 Reduced 5.02%
296,307 $4.48 Million
Q3 2018

Nov 14, 2018
BUY
$18.89 - $20.49 $162,095 - $175,824
8,581 Added 2.83%
311,975 $6.37 Million
Q2 2018

Aug 14, 2018
BUY
$18.13 - $19.4 $531,136 - $568,342
29,296 Added 10.69%
303,394 $5.7 Million
Q1 2018

May 14, 2018
BUY
$18.92 - $21.52 $512,353 - $582,761
27,080 Added 10.96%
274,098 $5.27 Million
Q4 2017

Feb 14, 2018
BUY
$18.31 - $22.24 $2.58 Million - $3.14 Million
140,994 Added 132.98%
247,018 $4.85 Million
Q3 2017

Nov 13, 2017
SELL
$20.12 - $21.88 $66,154 - $71,941
-3,288 Reduced 3.01%
106,024 $2.28 Million
Q2 2017

Aug 14, 2017
BUY
N/A
109,312
109,312 $2.28 Million

Others Institutions Holding HQL

# of Institutions
77
Shares Held
9.31M
Call Options Held
0
Put Options Held
0
View Full List

About TEKLA LIFE SCIENCES INVESTORS

HQL Quotes by TradingView
  • Ticker HQL
  • Exchange NYSE
  • Sector Financial Services
  • Industry Asset Management
  • Description
  • Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical...
More about HQL
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email